[go: up one dir, main page]

MX2018010037A - Pemetrexed formulations. - Google Patents

Pemetrexed formulations.

Info

Publication number
MX2018010037A
MX2018010037A MX2018010037A MX2018010037A MX2018010037A MX 2018010037 A MX2018010037 A MX 2018010037A MX 2018010037 A MX2018010037 A MX 2018010037A MX 2018010037 A MX2018010037 A MX 2018010037A MX 2018010037 A MX2018010037 A MX 2018010037A
Authority
MX
Mexico
Prior art keywords
pemetrexed
formulations
pemetrexed formulations
directed
stored
Prior art date
Application number
MX2018010037A
Other languages
Spanish (es)
Inventor
Jing Chen Feng-
L Krill Steven
Original Assignee
Eagle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc
Publication of MX2018010037A publication Critical patent/MX2018010037A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención está dirigida a formulaciones de pemetrexed que comprenden un solvente no acuoso que permanece estable después de su dilución durante al menos aproximadamente 48 horas cuando se almacena a una temperatura de 2 °C a 8 °C. La presente invención también está dirigida a formulaciones de pemetrexed que comprenden un solvente no acuoso que permanece estable durante al menos aproximadamente 24 meses cuando se almacena a una temperatura de 2 °C a 8 °C.The present invention is directed to formulations of pemetrexed comprising a non-aqueous solvent that remains stable after dilution for at least about 48 hours when stored at 2 ° C to 8 ° C. The present invention is also directed to pemetrexed formulations that comprise a non-aqueous solvent that remains stable for at least about 24 months when stored at 2 ° C to 8 ° C.

MX2018010037A 2016-02-19 2016-02-19 Pemetrexed formulations. MX2018010037A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2016/018703 WO2017142556A1 (en) 2016-02-19 2016-02-19 Pemetrexed formulations

Publications (1)

Publication Number Publication Date
MX2018010037A true MX2018010037A (en) 2019-07-04

Family

ID=59625349

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022009547A MX2022009547A (en) 2016-02-19 2016-02-19 Pemetrexed formulations.
MX2018010037A MX2018010037A (en) 2016-02-19 2016-02-19 Pemetrexed formulations.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2022009547A MX2022009547A (en) 2016-02-19 2016-02-19 Pemetrexed formulations.

Country Status (9)

Country Link
EP (1) EP3416646A4 (en)
JP (1) JP2019505561A (en)
KR (2) KR102794126B1 (en)
CN (1) CN109152778B (en)
AU (3) AU2016393213B2 (en)
CA (1) CA3014755C (en)
IL (5) IL301291A (en)
MX (2) MX2022009547A (en)
WO (1) WO2017142556A1 (en)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6686365B2 (en) * 2000-02-04 2004-02-03 Eli Lilly And Company Pharmaceutical composition
WO2008021411A2 (en) * 2006-08-14 2008-02-21 Sicor Inc. Processes for the preparation of lyophilized pharmaceutically acceptable salts of pemetrexed diacid
US9655898B2 (en) * 2010-07-28 2017-05-23 Eagle Pharmaceuticals, Inc. Pharmaceutical compositions containing pemetrexed having extended storage stability
WO2013144814A1 (en) * 2012-03-27 2013-10-03 Fresenius Kabi Oncology Ltd. Stable ready-to-use pharmaceutical composition of pemetrexed
EP2666463A1 (en) * 2012-05-21 2013-11-27 Synthon BV Stabilized liquid composition comprising pemetrexed
SI2854768T1 (en) * 2012-05-30 2017-08-31 Fresenius Kabi Oncology Limited Pharmaceutical compositions of pemetrexed
WO2013179310A1 (en) * 2012-05-31 2013-12-05 Mylan Laboratories Limited Stable aqueous compositions of pemetrexed
JP6099557B2 (en) * 2013-12-27 2017-03-22 富士フイルム株式会社 Injection solution preparation and method for producing the same
KR101703980B1 (en) * 2013-12-30 2017-02-08 주식회사 삼양바이오팜 Antioxidant-free pharmaceutical composition and preparation method thereof
LT3206666T (en) * 2014-10-16 2020-03-10 Synthon B.V. Liquid pharmaceutical composition comprising pemetrexed

Also Published As

Publication number Publication date
IL290647B2 (en) 2023-08-01
IL290647B1 (en) 2023-04-01
AU2023202089B2 (en) 2025-05-29
CN109152778A (en) 2019-01-04
IL261179B (en) 2022-03-01
IL324306A (en) 2025-12-01
AU2025223868A1 (en) 2025-09-18
KR20180132643A (en) 2018-12-12
CA3014755A1 (en) 2017-08-24
AU2016393213A1 (en) 2018-10-04
WO2017142556A1 (en) 2017-08-24
EP3416646A1 (en) 2018-12-26
IL312427B1 (en) 2025-12-01
IL312427A (en) 2024-06-01
EP3416646A4 (en) 2019-09-04
KR20240049356A (en) 2024-04-16
MX2022009547A (en) 2022-09-09
IL261179A (en) 2018-10-31
CA3014755C (en) 2023-11-14
CN109152778B (en) 2021-08-10
KR102794126B1 (en) 2025-04-11
IL290647A (en) 2022-04-01
JP2019505561A (en) 2019-02-28
AU2023202089A1 (en) 2023-06-01
IL301291A (en) 2023-05-01
AU2016393213B2 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
CL2017002727A1 (en) Compositions of obetolic acid and methods of use
CL2017001675A1 (en) Quinazoline derivatives used to treat HIV
AR122552A2 (en) STABLE IMMUNOGLOBULIN AQUEOUS COMPOSITION DURING STORAGE AND METHOD FOR STABILIZING AN IMMUNOGLOBULIN COMPOSITION
MX2022012313A (en) OXISTEROLS AND METHODS OF USE THEREOF.
CL2018001223A1 (en) Optimal locus of soy (application division 201601063)
CR20160499A (en) STABLE COMPOSITIONS OF IODINE NOT IN COMPLEX AND METHODS OF USE
CL2018000730A1 (en) Heterocyclic compounds and uses thereof
MX2015011311A (en) New octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors.
MX2019001096A (en) Tlr7/8 antagonists and uses thereof.
CU20200051A7 (en) BICYCLIC HETEROCYCLIC COMPONENTS REPLACED AS PRMT5 INHIBITORS
DOP2015000270A (en) POTENTIAL OF INHIBITORS OF THE HOMOLOGIST OF ZESTE
CR20180072A (en) NEW BICYCLE COMPOUNDS AS ATX INHIBITORS
EA201890899A1 (en) PHARNESIDE X-RECEPTOR MODULATORS
CL2017001923A1 (en) 9h-pyrrolo-dipyridine derivatives
MX2018010224A (en) UREASAS INHIBITING LIQUID FORMULATIONS.
MA38583B1 (en) Derivatives of dolastatin 10 and auristatines
MX2017007377A (en) ORGANIC COMPOUNDS.
CO7111275A2 (en) Bridgehead cyclic ether dgat1 inhibitors
AR103350A1 (en) COMPOSITIONS OF THE NITRIFICATION INHIBITOR AND METHODS OF PREPARATION OF THE SAME
CL2017002694A1 (en) Methods for hydraulic crop improvement
EA201500931A1 (en) PYRIDIN-4-ILA DERIVATIVES
WO2016137969A3 (en) Liquid levothyroxine formulations
MX2018006802A (en) Phenyl derivatives as cannabinoid receptor 2 agonists.
AR103230A1 (en) PROCESSES FOR THE PREPARATION OF A DIARILTIOHIDANTOINE COMPOUND
MX387796B (en) AMINOCARBONYLCRBAMATE COMPOUNDS.